All In Biotech

Drug Trial Radar · NCT03726294

A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Patients With Advanced Cancer

A Phase 1, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Efficacy of NBM-BMX in Subjects With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

33

Actual

Start

Oct 16, 2018

Primary completion

Apr 24, 2020

Study completion Oct 25, 2021

Sponsor

Sponsor type
Industry
First posted
Oct 31, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

NBM-BMX is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by NatureWise. NBM-BMX is a histone deacetylase (HDAC) inhibitor and has been shown to be particularly active against HDAC8. The objectives of this study are to determine the safety profile of NBM-BMX, including identification of dose limiting toxicity (DLT) and maximum tolerated dose (MTD), and to determine the Recommended Phase 2 Dose (RP2D).

Conditions

  • Malignant Neoplasm

Interventions

  • NBM-BMX softgel capsulesDrug

    Patients will initially receive NBM-BMX orally once a day at 100 mg per day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicity (DLT) of NBM-BMX [Safety and Tolerability]Time frame: up to 28 days
  2. Maximum tolerated dose (MTD) of NBM-BMX [Safety and Tolerability]Time frame: up to 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • NEXT Oncology

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.